Literature DB >> 33077958

Discovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settings.

Marc Lipman1,2, Mahdad Noursadeghi3, Ibrahim Abubakar4, Rishi K Gupta5, Claire J Calderwood5, Alexei Yavlinsky6, Maria Krutikov5, Matteo Quartagno7, Maximilian C Aichelburg8, Neus Altet9,10, Roland Diel11,12, Claudia C Dobler13,14, Jose Dominguez15,16,17, Joseph S Doyle18,19, Connie Erkens20, Steffen Geis21, Pranabashis Haldar22, Anja M Hauri23, Thomas Hermansen24, James C Johnston25, Christoph Lange26,27,28,29, Berit Lange30, Frank van Leth28,31,32, Laura Muñoz33, Christine Roder18,19, Kamila Romanowski25, David Roth25, Martina Sester28,34, Rosa Sloot35, Giovanni Sotgiu28,36, Gerrit Woltmann22, Takashi Yoshiyama37, Jean-Pierre Zellweger28,38, Dominik Zenner5, Robert W Aldridge6, Andrew Copas5,7, Molebogeng X Rangaka5,7,39,40.   

Abstract

The risk of tuberculosis (TB) is variable among individuals with latent Mycobacterium tuberculosis infection (LTBI), but validated estimates of personalized risk are lacking. In pooled data from 18 systematically identified cohort studies from 20 countries, including 80,468 individuals tested for LTBI, 5-year cumulative incident TB risk among people with untreated LTBI was 15.6% (95% confidence interval (CI), 8.0-29.2%) among child contacts, 4.8% (95% CI, 3.0-7.7%) among adult contacts, 5.0% (95% CI, 1.6-14.5%) among migrants and 4.8% (95% CI, 1.5-14.3%) among immunocompromised groups. We confirmed highly variable estimates within risk groups, necessitating an individualized approach to risk stratification. Therefore, we developed a personalized risk predictor for incident TB (PERISKOPE-TB) that combines a quantitative measure of T cell sensitization and clinical covariates. Internal-external cross-validation of the model demonstrated a random effects meta-analysis C-statistic of 0.88 (95% CI, 0.82-0.93) for incident TB. In decision curve analysis, the model demonstrated clinical utility for targeting preventative treatment, compared to treating all, or no, people with LTBI. We challenge the current crude approach to TB risk estimation among people with LTBI in favor of our evidence-based and patient-centered method, in settings aiming for pre-elimination worldwide.

Entities:  

Mesh:

Year:  2020        PMID: 33077958     DOI: 10.1038/s41591-020-1076-0

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  47 in total

Review 1.  Latent Mycobacterium tuberculosis infection.

Authors:  Haileyesus Getahun; Alberto Matteelli; Richard E Chaisson; Mario Raviglione
Journal:  N Engl J Med       Date:  2015-05-28       Impact factor: 91.245

Review 2.  Gamma interferon release assays for detection of Mycobacterium tuberculosis infection.

Authors:  Madhukar Pai; Claudia M Denkinger; Sandra V Kik; Molebogeng X Rangaka; Alice Zwerling; Olivia Oxlade; John Z Metcalfe; Adithya Cattamanchi; David W Dowdy; Keertan Dheda; Niaz Banaei
Journal:  Clin Microbiol Rev       Date:  2014-01       Impact factor: 26.132

Review 3.  The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis.

Authors:  Hannah Alsdurf; Philip C Hill; Alberto Matteelli; Haileyesus Getahun; Dick Menzies
Journal:  Lancet Infect Dis       Date:  2016-08-10       Impact factor: 25.071

4.  LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement.

Authors:  U Mack; G B Migliori; M Sester; H L Rieder; S Ehlers; D Goletti; A Bossink; K Magdorf; C Hölscher; B Kampmann; S M Arend; A Detjen; G Bothamley; J P Zellweger; H Milburn; R Diel; P Ravn; F Cobelens; P J Cardona; B Kan; I Solovic; R Duarte; D M Cirillo
Journal:  Eur Respir J       Date:  2009-05       Impact factor: 16.671

Review 5.  Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis.

Authors:  Molebogeng X Rangaka; Katalin A Wilkinson; Judith R Glynn; Daphne Ling; Dick Menzies; Judith Mwansa-Kambafwile; Katherine Fielding; Robert J Wilkinson; Madhukar Pai
Journal:  Lancet Infect Dis       Date:  2011-08-16       Impact factor: 25.071

6.  Revisiting the timetable of tuberculosis.

Authors:  Marcel A Behr; Paul H Edelstein; Lalita Ramakrishnan
Journal:  BMJ       Date:  2018-08-23

7.  Prognostic value of interferon-γ release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): a prospective cohort study.

Authors:  Ibrahim Abubakar; Francis Drobniewski; Jo Southern; Alice J Sitch; Charlotte Jackson; Marc Lipman; Jonathan J Deeks; Chris Griffiths; Graham Bothamley; William Lynn; Helen Burgess; Bobby Mann; Ambreen Imran; Saranya Sridhar; Chuen-Yan Tsou; Vladyslav Nikolayevskyy; Melanie Rees-Roberts; Hilary Whitworth; Onn Min Kon; Pranab Haldar; Heinke Kunst; Sarah Anderson; Andrew Hayward; John M Watson; Heather Milburn; Ajit Lalvani
Journal:  Lancet Infect Dis       Date:  2018-08-30       Impact factor: 71.421

8.  Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020.

Authors:  Timothy R Sterling; Gibril Njie; Dominik Zenner; David L Cohn; Randall Reves; Amina Ahmed; Dick Menzies; C Robert Horsburgh; Charles M Crane; Marcos Burgos; Philip LoBue; Carla A Winston; Robert Belknap
Journal:  MMWR Recomm Rep       Date:  2020-02-14

Review 9.  Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.

Authors:  Haileyesus Getahun; Alberto Matteelli; Ibrahim Abubakar; Mohamed Abdel Aziz; Annabel Baddeley; Draurio Barreira; Saskia Den Boon; Susana Marta Borroto Gutierrez; Judith Bruchfeld; Erlina Burhan; Solange Cavalcante; Rolando Cedillos; Richard Chaisson; Cynthia Bin-Eng Chee; Lucy Chesire; Elizabeth Corbett; Masoud Dara; Justin Denholm; Gerard de Vries; Dennis Falzon; Nathan Ford; Margaret Gale-Rowe; Chris Gilpin; Enrico Girardi; Un-Yeong Go; Darshini Govindasamy; Alison D Grant; Malgorzata Grzemska; Ross Harris; C Robert Horsburgh; Asker Ismayilov; Ernesto Jaramillo; Sandra Kik; Katharina Kranzer; Christian Lienhardt; Philip LoBue; Knut Lönnroth; Guy Marks; Dick Menzies; Giovanni Battista Migliori; Davide Mosca; Ya Diul Mukadi; Alwyn Mwinga; Lisa Nelson; Nobuyuki Nishikiori; Anouk Oordt-Speets; Molebogeng Xheedha Rangaka; Andreas Reis; Lisa Rotz; Andreas Sandgren; Monica Sañé Schepisi; Holger J Schünemann; Surender Kumar Sharma; Giovanni Sotgiu; Helen R Stagg; Timothy R Sterling; Tamara Tayeb; Mukund Uplekar; Marieke J van der Werf; Wim Vandevelde; Femke van Kessel; Anna van't Hoog; Jay K Varma; Natalia Vezhnina; Constantia Voniatis; Marije Vonk Noordegraaf-Schouten; Diana Weil; Karin Weyer; Robert John Wilkinson; Takashi Yoshiyama; Jean Pierre Zellweger; Mario Raviglione
Journal:  Eur Respir J       Date:  2015-09-24       Impact factor: 16.671

10.  Absolute risk of tuberculosis among untreated populations with a positive tuberculin skin test or interferon-gamma release assay result: systematic review and meta-analysis.

Authors:  Jonathon R Campbell; Nicholas Winters; Dick Menzies
Journal:  BMJ       Date:  2020-03-10
View more
  12 in total

1.  [24/f-Chronic cough : Preparation for the medical specialist examination: part 45].

Authors:  J Sachsenweger; K Miriam Scheu; C Lange; E Terhalle
Journal:  Internist (Berl)       Date:  2021-06       Impact factor: 0.743

2.  Does BCG vaccination protect against infection with M. tuberculosis?

Authors:  P T Pelzer; Y Smit; E W Tiemersma; N T Huong; N V Nhung; F Cobelens
Journal:  Int J Tuberc Lung Dis       Date:  2022-06-01       Impact factor: 3.427

3.  Personalized risk predictor for acute cellular rejection in lung transplant using soluble CD31.

Authors:  Philippe Montravers; Giuseppina Caligiuri; Alexy Tran-Dinh; Quentin Laurent; Guillaume Even; Sébastien Tanaka; Brice Lortat-Jacob; Yves Castier; Hervé Mal; Jonathan Messika; Pierre Mordant; Antonino Nicoletti; Ian Morilla
Journal:  Sci Rep       Date:  2022-10-21       Impact factor: 4.996

Review 4.  Tuberculosis in Adolescents and Young Adults: Emerging Data on TB Transmission and Prevention among Vulnerable Young People.

Authors:  Katherine M Laycock; Leslie A Enane; Andrew P Steenhoff
Journal:  Trop Med Infect Dis       Date:  2021-08-05

5.  Cost-effectiveness of newer technologies for the diagnosis of Mycobacterium tuberculosis infection in Brazilian people living with HIV.

Authors:  Ricardo E Steffen; Marcia Pinto; Afranio Kritski; Anete Trajman
Journal:  Sci Rep       Date:  2020-12-11       Impact factor: 4.379

6.  The burden and predictors of latent tuberculosis infection among immigrants in South Korea: a retrospective cross-sectional study.

Authors:  Sarah Yu; Dawoon Jeong; Hongjo Choi
Journal:  BMC Infect Dis       Date:  2021-12-03       Impact factor: 3.090

7.  Residual symptoms, lung function, and imaging findings in patients recovering from SARS-CoV-2 infection.

Authors:  Fares Darawshy; Ayman Abu Rmeileh; Rottem Kuint; Dan Padawer; Khalil Karim; Zvi Fridlender; Uri Laxer; Polina Goychman Cohen; Neville Berkman
Journal:  Intern Emerg Med       Date:  2022-03-02       Impact factor: 5.472

8.  New Insights into the Limitations of Host Transcriptional Biomarkers of Tuberculosis.

Authors:  Mahdad Noursadeghi; Rishi K Gupta
Journal:  Am J Respir Crit Care Med       Date:  2021-12-15       Impact factor: 21.405

9.  Clinical predictors of pulmonary tuberculosis among South African adults with HIV.

Authors:  Simon C Mendelsohn; Andrew Fiore-Gartland; Denis Awany; Humphrey Mulenga; Stanley Kimbung Mbandi; Michèle Tameris; Gerhard Walzl; Kogieleum Naidoo; Gavin Churchyard; Thomas J Scriba; Mark Hatherill
Journal:  EClinicalMedicine       Date:  2022-03-05

10.  Anticipating the future: prognostic tools as a complementary strategy to improve care for patients with febrile illnesses in resource-limited settings.

Authors:  Arjun Chandna; Jennifer Osborn; Quique Bassat; David Bell; Sakib Burza; Valérie D'Acremont; B Leticia Fernandez-Carballo; Kevin C Kain; Mayfong Mayxay; Matthew Wiens; Sabine Dittrich
Journal:  BMJ Glob Health       Date:  2021-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.